RxDoctor Payments Data

Kenneth Jutzy, MD

Interventional Cardiology · Loma Linda, CANPI 1073531802

Payments from drug & device makers

$2,523in general payments, 2019–2025

Across 51 payments — averaging $49.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Abiomed$448
  • Boston Scientific$407
  • Biotronik Inc.$193
  • Biosense Webster, Inc.$166
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$127
  • plus $139 from 3 others
$123in research payments, 2019–2025

Across 1 payment — averaging $123.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ZOLL Circulation Inc$123

What the payments were for

  • Travel & lodging$37915%
  • Food & beverage$2,14485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,523 in reported general payments places this provider in the 20th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$93,397
Medicare patients
633
Services billed
1,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$88,433
EntrestoSacubitril/Valsartan34$31,987
XareltoRivaroxaban21$30,626
BrilintaTicagrelor19$10,497
Repatha SyringeEvolocumab12$6,412
Nitroglycerin58$2,891
Metoprolol Succinate178$2,650
Atorvastatin Calcium155$1,997
Losartan Potassium138$1,178
Rosuvastatin Calcium67$1,164
Ranolazine ErRanolazine13$840
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$838
Flecainide Acetate14$838
Isosorbide Mononitrate ErIsosorbide Mononitrate54$736
Warfarin Sodium46$732

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →